Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03862846
Study type Interventional
Source Reneo Pharma Ltd
Contact
Status Terminated
Phase Phase 1
Start date May 10, 2019
Completion date April 23, 2020

See also
  Status Clinical Trial Phase
Terminated NCT03323749 - A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension Phase 3
Completed NCT04535609 - An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients Phase 2
Terminated NCT04641962 - A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy Phase 2
Terminated NCT05267574 - An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) Phase 2/Phase 3